Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 828,958 shares, an increase of 57.1% from the May 14th total of 527,786 shares. Based on an average daily volume of 263,322 shares, the days-to-cover ratio is presently 3.1 days. Currently, 15.7% of the shares of the company are sold short.

Moleculin Biotech Stock Down 0.2%

NASDAQ:MBRX traded down $0.01 on Tuesday, reaching $2.71. 118,284 shares of the company’s stock traded hands, compared to its average volume of 181,175. The stock has a 50-day simple moving average of $2.47 and a 200-day simple moving average of $3.37. The firm has a market cap of $14.44 million, a PE ratio of -0.15 and a beta of 1.77. Moleculin Biotech has a 12 month low of $1.79 and a 12 month high of $24.00.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21). On average, equities analysts anticipate that Moleculin Biotech will post -5.1 earnings per share for the current year.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on MBRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Tuesday, April 21st. Wall Street Zen cut Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Moleculin Biotech in a report on Tuesday, March 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $22.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.